Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

About this update from Denali Therapeutics Inc.

SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the opening plenary address, titled "Accelerating the Discovery and Development of Medicines for Neurodegeneration," at the Alzheimer's Association International Conference® (AAIC), taking place July 12-15 in London. Dr. Watts will discuss recent scientific advances and future opportunities including new insights in the biology of disease, the use of biomarkers for diagnosis and assessment of treatment effect, and the potential for therapeutics to cross the blood-brain barrier for enhanced delivery to the brain. "We are entering a new era of drug development for Alzheimer's disease, driven by significant developments in biology, biomarkers and the blood-brain barrier, which has been a major hurdle for the treatment of neurodegenerative disease," said Dr. Watts. "At Denali, our work has focused on solving the challenge of brain delivery so that people living with neurologic diseases such as Alzheimer's can benefit from the power of biotherapeutics. We are excited to be part of the community working to transform the lives of millions of individuals and families worldwide by applying these scientific breakthroughs to deliver the next generation of therapies for Alzheimer's disease." Denali Therapeutics has developed and clinically validated the TransportVehicle™, a proprietary technology designed to effectively deliver biologic therapeutics such as antibodies, enzymes and oligonucleotides across the blood-brain barrier by leveraging the body's natural iron transport system (the transferrin receptor). In March 2026, Denali received accelerated approval from the U.S. Food and Drug Administration for the first and only FDA-approved biologic specifically designed to cross the blood-brain barrier: AVLAYAH™ (tividenofusp alfa-eknm), an enzyme replacement therapy for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.

View stock analysis, news, and events for Denali Therapeutics Inc.